NYSEAMERICAN:MTNB

Matinas Biopharma Q3 2026 Earnings Results & Report

Matinas Biopharma logo
$0.91 +0.05 (+6.35%)
As of 04:10 PM Eastern

Matinas Biopharma reported Q3 2026 earnings on November 16, 2026. The company reported EPS of -$9.35.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

Matinas Biopharma EPS Results

Actual EPS
-$9.35
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 4 quarters

Matinas Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Matinas Biopharma Q3 2026 Earnings FAQ

Matinas Biopharma (NYSEAMERICAN:MTNB) reported earnings of -$9.35 per share for Q3 2026. The report was announced on Monday, November 16, 2026.

Matinas Biopharma Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Matinas Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Matinas Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Matinas Biopharma and other key companies, straight to your email.

About Matinas Biopharma

Matinas Biopharma (NYSEAMERICAN:MTNB) is a biopharmaceutical company focused on developing medicines using its lipid nanocrystal (LNC) delivery technology. The platform is designed to help deliver drugs that can be difficult to administer or absorb, including through oral formulations.

The company’s development programs have included MAT2203, an oral formulation of amphotericin B studied for serious fungal infections, and MAT2501, an oral formulation of amikacin investigated for difficult-to-treat bacterial infections. These programs have been intended to offer alternatives to conventional routes of administration.

Matinas has also explored its LNC platform for delivering other types of therapeutics. Its work has primarily centered on drug development rather than selling a broad range of commercial medicines.

View Matinas Biopharma Profile